[Form 4] BioCardia, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider purchase reported for BioCardia, Inc. (BCDA). Peter Altman, the company's President, CEO and a director, purchased 48,000 shares of common stock at $1.25 per share on 09/19/2025 through a public offering that closed that day, and received 48,000 warrants exercisable at $1.25 expiring 09/20/2027. After the transaction Mr. Altman beneficially owned 216,762 shares of common stock and 143,612 derivative securities (warrants/options) on a direct basis. The Form 4 was signed under power of attorney on 09/23/2025.

Positive

• Insider participation: CEO/Director purchased 48,000 shares and received 48,000 warrants in the issuer offering, showing direct capital commitment
• Transparent disclosure: Form 4 provides explicit purchase price ($1.25), exercise price ($1.25), exercise/expiration dates (09/19/2025–09/20/2027) and post-transaction ownership figures

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider acquisition of equity and matching warrants; increases direct ownership materially.

The filing shows a direct purchase of 48,000 common shares at $1.25 with attached warrants, raising reported direct common stock ownership to 216,762 shares and total derivatives to 143,612. This is a cash subscription in a public offering rather than an open-market trade, so share count and potential dilution from warrants are explicit in the filing. The explicit price and exercisability/expiry terms allow straightforward modelling of potential dilution and cash inflow if warrants are exercised.

Corporate Governance Expert

TL;DR: CEO and director participation in issuer offering documented; clear reporting and POA signature.

The Form 4 identifies Peter Altman as both an officer and director and discloses the purchase and accompanying warrants from the issuer's public offering. Reporting was completed via power of attorney and includes conversion/exercise terms (exercise price $1.25; expiry 09/20/2027). The filing provides required disclosure of beneficial ownership levels post-transaction, meeting Section 16 transparency requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		P		48,000(1)	A	$1.25(1)	216,762	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (right to buy)	$1.25	09/19/2025		P		48,000(1)		09/19/2025	09/20/2027	Common Stock	48,000(1)	(1)	143,612	D

Explanation of Responses:

1. These shares were purchased from the Issuer in a public offering that closed on September 19, 2025, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased.

	/s/ David McClung, by power of attorney	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Peter Altman report on the Form 4 for BCDA?

He reported purchasing 48,000 common shares at $1.25 and receiving 48,000 warrants exercisable at $1.25 expiring 09/20/2027; post-transaction he beneficially owned 216,762 shares and 143,612 derivative securities

When was the transaction executed and reported for BCDA Form 4?

The transaction date (execution) is 09/19/2025; the Form 4 bears a signature by power of attorney dated 09/23/2025

What are the terms of the warrants received in the BCDA transaction?

Each warrant has an exercise price of $1.25, was issued 09/19/2025 and expires on 09/20/2027; 48,000 warrants were received with the share purchase

How many shares did the CEO own after the reported BCDA transaction?

Following the transaction the filing reports 216,762 shares of common stock beneficially owned on a direct basis